We are live on ! Find out more
STLN icon

Starling Oncology
STLN

6.94 USD
+0.60
9.46%
At close Updated Nov 4, 4:00 PM EST
Pre-market
After hours
6.92
-0.02
0.29%
1 day
9.46%
5 days
4.36%
1 month
10.16%
3 months
34.24%
6 months
70.1%
Year to date
89.1%
1 year
63.68%
5 years
-30.46%
10 years
-28.45%
 

About: Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.

Employees: 641

Healthcare Medical Care Facilities

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 11.1%
Neutral 77.8%
Negative 11.1%
Neutral
GlobeNewsWire
9 days ago
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2026 financial results on Thursday, November 5, 2026, to be followed by a conference call the same day at 5:00 p.m.
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
Neutral
Seeking Alpha
28 days ago
Cedar Grove Capital Q3 2026 Portfolio Update
During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.
Cedar Grove Capital Q3 2026 Portfolio Update
Neutral
GlobeNewsWire
1 month ago
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Positive
Seeking Alpha
1 month ago
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating
Starling Oncology is rated BUY, supported by strong secular growth and expanding adoption of its oncology managed care services. STLN's revenue model leverages scalable delegation contracts, driving higher PMPM fees, pharmacy growth, and gross profit expansion. FY26 guidance was raised: revenue is up 31%, gross profit is up 41%, and positive EBITDA ($2–$7M) and free cash flow ($10M) are expected.
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating
Neutral
GlobeNewsWire
2 months ago
Starling Oncology to Participate in Wells Fargo Healthcare Conference
CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a fireside chat from 4:30–5:05 p.m.
Starling Oncology to Participate in Wells Fargo Healthcare Conference
Neutral
GlobeNewsWire
2 months ago
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care's persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
Neutral
Seeking Alpha
2 months ago
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
Starling Oncology, Inc. (STLN) Q2 2026 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
The Oncology Institute, Inc. (STLN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Neutral
GlobeNewsWire
3 months ago
The Oncology Institute Rebrands as Starling Oncology
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.
The Oncology Institute Rebrands as Starling Oncology
See News Rankings
Price charts implemented using Lightweight Charts™